Tumor Infiltrating Lymphocytes in Renal Cell Cancer
For the past decade the immunotherapy approach to the treatment of solid cancers resistant to conventional treatment modalities has proven to be of benefit, particularly in melanoma and metastatic renal cell cancer. Cancer patients were treated with the lymphokine interleukin-2 (IL-2) alone, or in combination with other lymphokines in order to activate the patient’s immune system against the cancer. Alternatively, autologous circulating lymphocytes obtained by leukapheresis of the patient were activated and expanded with IL-2 in vitro, leading to the generation of lymphokine-activated killer (LAK) cells. These LAK cells capable of mediating a high degree of antitumor activity were reinfused to the patients in combination with IL-2 administration, thus providing the patient with a large pool of killer cells. Following LAK cell therapy for renal cell cancer 35% partial and complete response rates have been achieved with many durable responses and several patients who are still in remission after 3 years .
KeywordsToxicity Ischemia Chromium Oncol Interferon
Unable to display preview. Download preview PDF.
- 8.Finke JH, Tubbs R, Connelly R, Pontes E, Montie J (1988) Tumor infiltrating lymphocytes in patients with renal cell carcinoma. In: Battisto J, Plate J, Shearer G (eds) Cytotoxic T cells: biology and relevance to disease. New York Academy of Science pp 387–394Google Scholar
- 15.Li WY, Lusheng S, Kanbour A, Herberman RB, Whiteside TL (1989) Lymphocytes infiltrating human ovarian tumors: synergy between tumor necrosis factor and interleukin 2 in the generation of CD8+ effectors from tumor-infiltrating lymphocytes. Cancer Res 49: 5979–5985Google Scholar
- 22.Slingluff CL, Darrow TL, Seigler HF (1987) Human T cells specifically activated against autologous malignant melanoma. Arch Surg 122: 1207–1411Google Scholar
- 23.Spiess PJ, Yang JC, Rosenberg SA (1987) In vivo antitumor activity of tumor infiltrating lymphocytes expanded in recombinant interleukin 2. JNCI 75: 1067–1075Google Scholar
- 24.Stotter H, Wiebke EA, Tomita S, Belldegrun A, Topalian S, Rosenberg SA, Lotze MT (1989) Cytokines alter target cell susceptibility to lysis. II. Evaluation of tumor infiltrating lymphocytes. J Immunol 142: 1767–1773Google Scholar
- 27.Vose BM, Moore M (1985) Human tumor-infiltrating lymphocytes: a marker of host response. Semin Hematol 11: 27–40Google Scholar